Introduction {#s1}
============

Liver transplantation (LT) is a validated treatment for hepatocellular carcinoma (HCC) ([@B1], [@B2]). The risk of HCC recurrence varies between 8 and 20% depending on pre-transplant-variables such as the tumor burden and the alpha-fetoprotein (AFP) level ([@B3]--[@B7]). Moreover, HCC recurrence after LT is an accepted and not exceptional clinical challenge ([@B8]). In fact, it reduces LT curative intention, being the survival reduced as low as 3.3 months when only best supportive care is offered ([@B9]). Surveillance and administration of HCC recurrence after LT is exciting and complicated. More frequently, recurrence occurs within the first 2 years ([@B10]), although cases of very late recurrence after a 10 year period have been reported ([@B11], [@B12]).

Regarding the sites of HCC recurrence, the first revelation is more frequently extra-hepatic (as high as 71%), followed by intra-hepatic and simultaneously intra- and extra-hepatic ([@B13]). In addition, intra- or extrahepatic recurrence, or the combination of both, did not result in different outcomes. Among the extrahepatic sites of recurrence, the lung is the most frequent metastatic site ([@B5]). Pulmonary metastases resection (PMR) for HCC improves survival in patients treated by liver resection or ablative procedures ([@B14]). Although some investigators recommend PMR also for HCC recurrence after LT ([@B15], [@B16]), in this setting the impact on survival is unclear and today pulmonary metastases for HCC (PM-HCC) after LT are infrequently resected due to their multiplicity and multi-organ involvement.

To give new lights on this issue, we report the experience of three Italian LT Centers regarding pulmonary metastasectomy for HCC after LT in terms of safety, complication, risk of recurrence, and survival.

Patients and Methods {#s2}
====================

Study Design, Patients, and Endpoints
-------------------------------------

This is a retrospective evaluation of a cohort of prospectively enrolled patients in three different Liver Transplant Centers in Italy (two in Milan and one in Padua). All consecutive HCC transplanted patients, who developed PM-HCC, as first metastasis, from 2008 to 2018 were included in this study whenever treated with lung surgery resection. The database was locked in June 2019. Baseline corresponded to first HCC recurrence after LT with lung metastases. Each patient signed a written informed consent in conformity with the ethic committee and the ethical guidelines of the 1975 Declaration of Helsinki, as updated in 2004.

A contrast-enhanced thoraco-abdominal computed tomography (CT)-scan was performed every 6 months for the first 5 years, and then annually in all HCC transplanted patients. Serum AFP was quantified every 3 months during the first year and every 6 months thereafter. In case of suspected HCC recurrence, biopsy was performed when the site of recurrence is reachable. Otherwise, the diagnosis was obtained by imaging associated with AFP levels increase. Once the diagnosis was obtained, surgery treatment was performed whenever judged appropriate, with a curative or palliative intent. For the analysis, treatments were considered with a curative intent if the removal of the neoplastic lesion led the patient HCC-free.

Once the diagnosis was obtained, in one of the three centers sorafenib was started as soon as became available and its use safe (i.e., after healing of surgical wound in surgical patients) and mammalian target of rapamycin inhibitor (mTORi)-based immunosuppression regimen (sirolimus or everolimus) was considered.

The following data were collected: demographics and pre-LT history, native liver histological tumor staging, immunosuppressive regimens, time, characteristics and treatments of HCC recurrence, surgery procedures, and complications.

The primary endpoint was safety of surgery on lung metastasis in HCC recurrent patients after LT. Secondary endpoints were feasibility of surgery in these patients, recurrence after the first surgical treatment and survival.

Surgery safety was assessed with evaluations of multiple parameters: perioperative in-hospital mortality (considered as death for any causes during post-operative in-hospital course), 30 days mortality (considered as death for any causes within 30 days after thoracic surgery), surgical skin-to-skin time, post-operative hospital stay, need of post-operative intensive care unit (ICU), blood transfusions, readmission rate, post-operative complications. We considered as complication any of the following: bleeding, pneumonia, major cardiac complications (atrial fibrillation or acute myocardial ischemia), persistent air leak \>7 days, wound infection or dehiscence, acute kidney injury (AKI). A CT-scan every 2 months after surgery and during follow-up was used to assess tumor response, according to modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria ([@B17]). Time to radiological progression was defined as the time elapsed from baseline to disease progression according to modified RECIST criteria for HCC. Overall survival (OS) was measured from the date of first surgical intervention until the date of death from any cause or date of the last visit. Baseline variables were also analyzed in order to identify predictors of OS.

Surgery
-------

Patients with suspected or diagnosed thoracic metastasis from HCC have been referred to thoracic surgery department. Firstly, all referred patients were screened and judged suitable or unsuitable for metastasectomy from surgical anatomical point of view. Considering the metastatic nature of the thoracic nodules, the intervention proposed was a minimally invasive lung-sparing resection, whenever possible. If positively judged for surgery, patients were functionally evaluated by cardio-pulmonary tests and, finally an anathesiological risk was formulated, according to the American Society of Anesthesiologists (ASA) physical status classification system. The intraoperative and post-operative management was carried out in a standard way.

Statistical Analysis
--------------------

We used standard statistics (median and range for continuous variables, percentage for categorical variables) to describe baseline series characteristics and safety data. Survival time was computed as the interval between first HCC recurrence and death (survival after recurrence). Survival time was censored at the date of last contact in living patients. Survival curves were estimated with the non-parametric Kaplan-Meier method. Calculations were done using SPSS Statistics Program.

Results {#s3}
=======

Twenty-five patients were enrolled. Patients\' baseline characteristics are shown in [Table 1](#T1){ref-type="table"}. HCC recurred after a median of 33.6 months (8.9--306.4) since LT. PM-HCC treatment was performed after a median of 2.4 months (0--43.1) following HCC recurrence. A total of 28 PMR (19 single resections; 9 multiple resections; 16 right; 2 left) have been performed on the 24 enrolled patients. In additional patient, transthoracic percutaneous microwave thermoablation (MWA) was preferred, due to the high risk for surgery. Four patients have been re-operated due to pulmonary HCC-recurrence after the first PMR. The majority of surgical resection type was wedge resection (*n* = 26, 89.2%), while only one segmentectomy and one lobectomy were performed. The surgical access was as follows: video-assisted thoracic surgery (VATS) in 17 cases (58.6%); thoracotomy (11 cases, 37.9%); MWA (1 case, 3.4%). None conversion from VATS to thoracotomy was needed. The presence of pleural adhesions was observed in 7 cases (24.1%). The average of nodules treated per procedure was 1.5 (1--4). The majority of nodule treated was in right lower lobe (12), followed by left lower lobe (7), left upper lobe (6), right upper lobe (4), and right middle lobe (3). In [Table 2](#T2){ref-type="table"} per-patient\'s characteristics were presented.

###### 

Baseline features of the 25 patients enrolled in the study.

  **Features**                                                   **Overall (*n* = 25)**
  -------------------------------------------------------------- ------------------------
  Age, years[^\*^](#TN1){ref-type="table-fn"}                    58 (41--73)
  Male, N.                                                       21 (84%)
  Smoke, N.                                                      8 (32%)
  COPD, N.                                                       5 (20%)
  FEV1, % of predicted[^\*^](#TN1){ref-type="table-fn"}          91 (76.1--124)
  CAD, N.                                                        0
  Diabetes, N.                                                   2 (8%)
  BMI, kg/m^2^[^\*^](#TN1){ref-type="table-fn"}                  27 (19--30)
  Anticoagulant or antiplatelet drugs, N.                        6 (24%)
  Cirrhosis, N.                                                  3 (12%)
  Liver disease etiology, N.                                     
    HCV                                                          13 (52%)
    HBV                                                          6 (24%)
    Other etiologies                                             6 (24%)
  Native liver histology, N.                                     
    Milan-in                                                     12 (48%)
    Microvascular invasion                                       11 (44%)
    Edmonson grade 3 or 4                                        9 (36%)
  HCC recurrence time, months[^\*^](#TN1){ref-type="table-fn"}   34 (9--306)
  HCC recurrence pattern, N.                                     
    Liver only                                                   0
    Intra and extra-hepatic                                      0
    Extra-hepatic only                                           25 (100%)
  AFP levels, ng/mL[^\*^](#TN1){ref-type="table-fn"}             7 (1--85)
  Immunosoppressive regimen, N.                                  
    CNi+mTORi                                                    4 (16%)
    mTORi                                                        3 (12%)
    CNi                                                          11 (44%)
    CNi+MMF                                                      7 (28%)

*Median (range); COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume at 1 s; CAD, coronary artery disease; BMI, body mass index, HCV, hepatitis C virus; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; AFP, alpha-fetoprotein; CNi, calcineurine inhibitor; mTORi, mammalian target of rapamycin inhibitor; MMF, mycofenolate*.

###### 

Individual surgery details and follow-up of the 25 patients enrolled in the study.

  **Patients**   **Gender, age (years)**   **Time to recurrence from OLT (months)**   **Nodules: number/size (mm)**   **PET scan**   **Resection**   **Lobe**   **Surgical access**   **ICU**      **Blood trasfusion**   **Surgery complications, type**   **HCC recurrence after surgery**    **Time of recurrence from surgery (months)**   **Site of recurrence after surgery**   **Polmonary surgery for recurrence**   **Follow-up (months)**   **Dead**
  -------------- ------------------------- ------------------------------------------ ------------------------------- -------------- --------------- ---------- --------------------- ------------ ---------------------- --------------------------------- ----------------------------------- ---------------------------------------------- -------------------------------------- -------------------------------------- ------------------------ ----------
  \#1            Male, 62                  92                                         1/18                            Pos            WEDGE           LUL        VATS                  No           No                     No                                Yes                                 8.7                                            Abdomen                                No                                     50                       No
  \#2            Male, 57                  57                                         1/NA                            NA             MWA             LUL        VATS                  No           No                     No                                [\*\*](#TN2){ref-type="table-fn"}   NA                                             NA                                     NA                                     39                       Yes
  \#3            Male, 58                  13                                         1/13                            Neg            WEDGE           RLL        VATS                  No           No                     No                                Yes                                 4.1                                            Lung                                   No                                     97                       No
  \#4            Female, 60                34                                         1/NA                            Pos            WEDGE           RUL        VATS                  No           No                     Yes, wound infection/dehiscence   No                                  NA                                             NA                                     NA                                     16                       No
  \#5            Male, 61                  18                                         1/12                            Neg            WEDGE           LLL        VATS                  No           No                     No                                [\*\*](#TN2){ref-type="table-fn"}   NA                                             NA                                     NA                                     26                       Yes
  \#6            Male, 58                  25                                         1/5                             Neg            WEDGE           RLL        VATS                  No           No                     No                                Yes                                 20.9                                           Lung                                   Yes                                    39                       Yes
  \#7            Male, 41                  9                                          3/NA                            NA             WEDGE           RLL, RUL   Thoracotomy           No           Yes                    Yes, haemothorax                  Yes                                 9.2                                            Multifocal                             No                                     31                       Yes
  \#8            Male, 51                  13                                         1/17                            Neg            WEDGE           LUL        VATS                  No           No                     No                                Yes                                 16.3                                           Liver                                  No                                     29                       Yes
  \#9            Male, 53                  15                                         1/4                             Pos            WEDGE           RUL        Thoracotomy           No           No                     No                                No                                  NA                                             NA                                     NA                                     23                       No
  \#10           Male, 60                  9                                          2/8                             NA             WEDGE           LLL        VATS                  No           No                     No                                Yes                                 5.3                                            Bone                                   No                                     7                        No
  \#11           Female, 43                36                                         3/7                             Pos            WEDGE           LLL        Thoracotomy           No           No                     No                                Yes                                 2.1                                            Lung                                   Yes                                    213                      No
  \#12           Female, 71                306                                        2/4                             Pos            WEDGE           RLL        Thoracotomy           Yes,3 days   No                     Yes, acute renal failure          No                                  NA                                             NA                                     NA                                     19                       No
  \#13           Male, 62                  62                                         1/12                            Neg            SEGMENTECTOMY   RLL        VATS                  No           Yes                    Yes, haemothorax                  No                                  NA                                             NA                                     NA                                     8                        No
  \#14           Male, 68                  42                                         1/17                            Neg            WEDGE           LLL        VATS                  No           No                     No                                Yes                                 1.5                                            Multifocal                             No                                     47                       No
  \#15           Male, 64                  1                                          1/10                            NA             WEDGE           LUL        VATS                  No           No                     No                                Yes                                 23.7                                           Multifocal                             No                                     33                       Yes
  \#16           Male, 68                  8                                          1/13                            NA             WEDGE           RLL        VATS                  No           No                     No                                No                                  NA                                             NA                                     NA                                     32                       No
  \#17           Male, 49                  6                                          2/12                            NA             WEDGE           RLL        VATS                  No           No                     No                                No                                  NA                                             NA                                     NA                                     32                       No
  \#18           Male, 51                  51                                         1/33                            Pos            WEDGE           ML         Thoracotomy           No           No                     No                                Yes                                 14.5                                           Multifocal                             No                                     21                       Yes
  \#19           Male, 68                  36                                         2/15                            Pos            WEDGE           LLL, LUL   Thoracotomy           No           No                     No                                Yes                                 15                                             Lung                                   No                                     51                       Yes
  \#20           Male, 70                  67                                         1/14                            Neg            LOBECTOMY       ML         VATS                  No           No                     No                                Yes                                 5.3                                            Liver                                  No                                     57                       No
  \#21           Male, 56                  50                                         1/6                             Neg            WEDGE           RLL        VATS                  No           No                     No                                No                                  NA                                             NA                                     NA                                     36                       No
  \#22           Male, 52                  14                                         1/22                            Pos            WEDGE           RLL        Thoracotomy           No           No                     No                                Yes                                 32.6                                           Lung                                   Yes                                    35                       No
  \#23           Male, 53                  20                                         1/13                            Pos            WEDGE           RLL        Thoracotomy           No           No                     No                                No                                  NA                                             NA                                     NA                                     12                       No
  \#24           Male, 58                  46                                         3/15                            Neg            WEDGE           LLL        VATS                  No           No                     No                                No                                  NA                                             NA                                     NA                                     18                       No
  \#25           Male, 73                  121                                        2/15                            Pos            WEDGE           LLL        Thoracotomy           No           No                     No                                No                                  NA                                             NA                                     NA                                     6                        No

*LLL, left lower lobe; LUL, left upper lobe; PET, positron emission tomography; LM, median lobe; RLL, right lower lobe; RUL, right upper lobe; ICU, intensive care unit*.

VATS, video-assisted thoracic surgery; MWA, percutaneous microwave ablation;

*Diagnostic surgery; Pos, positive; Neg, negative; NA, not available or not applicable*.

Safety Analysis
---------------

Perioperative in-hospital mortality and 30 days mortality were nil. Median surgical time (skin-to-skin) was 90 min (range 50--365); median post-operative overall stay was 5 days (range 2--11). Post-operative ICU treatment was necessary in 1 case only (3.4%), for 3 days. Blood transfusions were necessary in 2 cases (6.9%). Readmission was required in 1 case (3.4%). A total of 5 complications (2 bleeding; 1 AKI; 1 major cardiac; 1 wound dehiscence) were observed, with an overall complications occurrence of 22.7% (detailed in [Table 2](#T2){ref-type="table"}).

Effectiveness and Survival
--------------------------

The median follow-up after HCC recurrence was 32.5 months (7.4--213.0). Eight (32%) patients died: 7 for HCC progression, 1 patient for severe liver failure due to chronic rejection. The 1-, 3-, and 5 year cumulative probability of OS from recurrence were 100, 66% (95%IC 44--88) and 43% (95%CI 12--74), respectively, with a median OS of 51 months (95%CI 24--78) ([Figure 1](#F1){ref-type="fig"}).

![Cumulative survival (1, 3, and 5 year) of the 25 patients enrolled in the study after hepatocellular carcinoma recurrence following liver transplantation.](fonc-10-00381-g0001){#F1}

Discussion {#s4}
==========

This is the first study, to the best of our knowledge, to specifically evaluate the impact and management of lung metastases in HCC recurrence after LT. We observed a low occurrence of complications, no surgery-related mortality and a good feasibility of surgery in those patients judged operable after first RPM whenever HCC recurred in lung. We observed that the majority of recurrences were in the right lower lobe. This is probably due to the proximity of this site to the liver at the time of hepatectomy and to the lymphatic drainage. Finally, we detected good long-term survival outcomes, with a 1-, 3-, and 5 year cumulative probability of OS from recurrence of 100%, 66% (95%CI 44--88) and 43% (95%CI 12--74), respectively, and a median OS of 51 months (95%CI 24--78).

Our study would have a great impact in the setting of LT for HCC, since the second most common site of HCC recurrence is the lung. Whenever the lesions were limited to the lung, we were able to show that complete resection can be safely performed, which may have contributed to the long-term survival of these patients, while some reviews advocated more aggressive surgical intervention ([@B5], [@B6]). This is of great importance, since tumor recurrence would have obviously decreased the opportunity of long-term survival after LT for HCC ([@B6], [@B15]). To the best of our knowledge, only few reports of resection for pulmonary metastasis from HCC after liver transplantation are available ([@B15], [@B16], [@B18]--[@B22]). In particular, Bates et al. ([@B16]) reported five cases of metastatic HCC resection after liver transplantation, with a survival period of 44 months after LT and 28 months after pulmonary resection.

Finally, our results in terms of OS are comparable to those of patients following metastasectomy after liver resection for HCC in patients without history of LT ([@B14], [@B23]--[@B25]).

Although prognostic indicators are not known, several clinical or pathological factors have been published ([@B14], [@B23], [@B26], [@B27]). Generally, patient selection and metastasis characteristics (such as number and side of lesions) are indispensable for a surgery survival benefit. In additional, good liver function might be essential for better survival ([@B28], [@B29]). As confirmation of this, in our study population was well-selected (only lung metastasis) with a good liver function (no patients with decompensated disease).

After the metastasectomy, recurrence may be managed by a repeated metastasectomy ([@B23], [@B30]--[@B32]). In our series, 4 patients (3 cases for recurrence, once case to complete the resection) underwent to a second pulmonary resection for a recurrent PM-HCC after a metastasectomy. Multiple metastases or repeated metastasectomies are not risk factors for long-term survival, as shown in this and previous studies ([@B31], [@B33]), although patients with a single metastasis or single pulmonary surgery might show better survival ([@B23], [@B26]).

Limitations of our study are: the retrospective design, the lack of a control arm and the limited number of patients. The impact of surgical access on outcome cannot be assessed, due to the limited number of patients. However, the study has several strengths: this is the largest consecutive series of patients affected by lung HCC-metastasis treated surgery in the post-transplant setting. Moreover, despite the retrospective design of the study, the cohort is homogeneous regarding the baseline features and the patient management.

In conclusion, selected patients without intrahepatic HCC-recurrence after LT and with preserved hepatic function showed that a pulmonary metastasectomy could be efficacious in managing a PM-HCC and could give an opportunity for long-term survival.
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